Monoclonal Antibodies in Multiple Myeloma Come of Age
Mené sur 72 patients atteints d'un myélome multiple récidivant ou réfractaire, cet essai de phase I/II évalue la toxicité et l'efficacité, du point de vue de la réponse globale, du daratumumab, un anticorps monoclonal ciblant CD38
Multiple myeloma is a cancer of plasma cells that has an estimated incidence of 26,850 new patients in 2015 in the United States. In the past few years, dramatic progress has been made in the treatment of this disease. New classes of drugs, including proteasome inhibitors (e.g., bortezomib and carfilzomib) and immunomodulatory agents (e.g., lenalidomide and pomalidomide), have improved response rates and survival significantly, and it now appears that immunotherapy is likely to lead to even greater advances.